Recent advances in HER2-targeted inhibitors for cancer therapy
Wenjian Zhu, Xiaoyun Lu · 2026
Read Recent advances in HER2-targeted inhibitors for cancer therapy by Wenjian Zhu, Xiaoyun Lu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13312587.txt.
Description
Wenjian Zhu and Xiaoyun Lu review, in a 2026 article, recent progress in HER2-targeted kinase inhibitors for cancer. HER2 is a growth-signaling receptor. Its excess or mutation drives several cancers. Two decades of drug development have produced successive generations of these drugs. They run from reversible pan-HER drugs such as lapatinib to covalent successors such as neratinib. Newer, sharper agents include tucatinib.
The review's central problem is precision. HER2 activates in varied ways and mutates at many sites, including stubborn exon 20 insertions. Each tumor type behaves differently, so one drug rarely fits all. The authors catalogue how resistance emerges. They examine design strategies that sharpen targeting to cut off-target toxicity while defeating resistant mutants. Their roadmap points chemists and clinicians toward next-generation drugs matched to specific HER2 changes.
Catalog record
| CREATOR | Wenjian Zhu, Xiaoyun Lu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |